Vitamin D and diabetic nephropathy: A systematic review and meta-analysis

Nutrition

Volumn 31, Issue 10, 2015, Pages 1189-1194

  Derakhshanian, Hoda ^a   Shab Bidar, Sakineh ^a   Speakman, John R ^b   Nadimi, Hoda ^a   Djafarian, Kurosh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Cholecalciferol; Diabetes mellitus; Nephropathy

Indexed keywords

ALBUMIN; COLECALCIFEROL; CREATININE; PLACEBO; VITAMIN; VITAMIN D;

CHEMOLUMINESCENCE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETIC NEPHROPATHIES; DIETARY SUPPLEMENT; MIDDLE AGED;

CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIETARY SUPPLEMENTS; HUMANS; MIDDLE AGED; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84942296399     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2015.04.009     Document Type: Review

References (42)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014, 103:137-149.
2. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Physiol Rev 2013, 93:137-188.
3. Need A.G., O'Loughlin P.D., Horowitz M., Nordin B.E. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol (Oxf) 2005, 62:738-741.
4. Chiu K.C., Chu A., Go V.L., Saad M.F. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004, 79:820-825.
5. Shab-Bidar S., Neyestani T.R., Djazayery A., Eshraghian M.R., Houshiarrad A., Gharavi A., et al. Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial. BMC Med 2011, 9:125.
6. Shab-Bidar S., Neyestani T.R., Djazayery A., Eshraghian M.R., Houshiarrad A., Kalayi A., et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev 2012, 28:424-430.
7. Neyestani T.R., Djazayery A., Shab-Bidar S., Eshraghian M.R., Kalayi A., Zahedirad M., et al. Vitamin D Receptor Fok-I polymorphism modulates diabetic host response to vitamin D intake: need for a nutrigenetic approach. Diabetes Care 2013, 36:550-556.
8. Inukai T., Fujiwara Y., Tayama K., Aso Y., Takemura Y. Alterations in serum levels of 1, 25 (OH)2 D3 and osteocalcin in patients with early diabetic nephropathy. Diabetes Res Clin Pract 1997, 38:53-59.
9. Fernández-Juárez G., Luno J., Barrio V., de Vinuesa S.G., Praga M., Goicoechea M., et al. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol 2013, 8:1870-1876.
10. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 6:1115-1125.
11. Plum L., Zella J. Vitamin D compounds and diabetic nephropathy. Arch Biochem Biophys 2012, 523:87-94.
12. Zhang Y., Deb D.K., Kong J., Ning G., Wang Y., Li G., et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009, 297:F791-801.
13. De Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
14. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.as.
15. Moher D., Jadad A.R., Nichol G., Penman M., Tugwell P., Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995, 16:62-73.
16. Higgins J.P., Spiegelhalter D.J. Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. Int J Epidemiol 2002, 31:96-104.
17. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
18. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
19. Huang Y., Yu H., Lu J., Guo K., Zhang L., Bao Y., et al. Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy. PloS One 2012, 7:e50510.
20. Krairittichai U., Mahannopkul R., Bunnag S. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease. J Med Assoc Thai 2012, 95:S41-S47.
21. Ahmadi N., Mortazavi M., Iraj B., Askari G. Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients?. J Res Med Sci 2013, 18:374.
22. Mustafar R., Mohd R., Ahman Miswan N., Cader R., Gafor H.A., Mohamad M., et al. The effect of calcium with or without calcitriol supplementation on renal function in patients with hypovitaminosis D and chronic kidney disease. Nephrourol Mon 2014, 6:e13381.
23. Diaz V.A., Mainous A.G., Carek P.J., Wessell A.M., Everett C.J. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 2009, 22:521-527.
24. de Boer I.H., Sachs M.C., Cleary P.A., Hoofnagle A.N., Lachin J.M., Molitch J.M., et al. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab 2012, 97:4780-4788.
25. Vojtková J., Ciljakova M., Vojarova L., Janikova K., Michnova Z., Sagiova V. Hypovitaminosis D in children with type 1 diabetes mellitus and its influence on biochemical and densitometric parameters. Acta Medica. Hradec Králové 2012, 55:18-22.
26. Li D., Zhang Y., Ding B., Liu B.L., Jiang L.L., Xing C.Y., et al. Zhonghua Nei Ke Za zhi 2013, 52:970-974. [in Chinese].
27. Bajaj S., Singh R.P., Dwivedi N.C., Singh K., Gupta A., Mathur M. Vitamin D levels and microvascular complications in type 2 diabetes. Indian J Endocrinol Metab 2014, 18:537.
28. Dent C., Harper C.M., Philpot G. The treatment of renal-glomerular osteodystrophy. QJM 1961, 30:1-31.
29. de Boer I.H., Ioannou G.N., Kestenbaum B., Brunzell J.D., Weiss N.S. 25-hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007, 50:69-77.
30. Kim M.J., Frankel A.H., Donaldson M., Darch S.J., Pusey C.D., Hill P.D., et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011, 80:851-860.
31. Bonakdaran S., Hami M., Hatefi A. The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus. Saudi J Kidney Dis Transpl 2012, 23:1215.
32. Zhang Z., Sun L., Wang Y., Ning G., Minto A.W., Kong J., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2007, 73:163-171.
33. Norman A.W., Frankel J.B., Heldt A.M., Grodsky G.M. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980, 209:823-825.
34. Weiler H.A., Lowe J., Krahn J., Leslie W.D. Osteocalcin and vitamin D status are inversely associated with homeostatic model assessment of insulin resistance in Canadian Aboriginal and white women: the First Nations Bone Health Study. J Nutr Biochem 2013, 24:412-418.
35. Li Y.C., Qiao G., Uskokovic M., Xiang W., Zheng W., Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004, 89:387-392.
36. Aschenbrenner J., Sollinger H.W., Becker B.N., Hullett D.A. 1,25-(OH2) D3 alters the transforming growth factor (signaling pathway in renal tissue. J Surg Res 2001, 100:171-175.
37. Li Y., Spataro B.C., Yang J., Dai C., Liu Y. 1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005, 68:1500-1510.
38. Wu-Wong J.R., Nakane M., Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res 2006, 44:11-18.
39. Zehnder D., Quinler M., Eardley K.S., Bland R., Lepenies J., Hughes S.V., et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008, 74:1343-1353.
40. Helvig C.F., Cuerrier D., Hosfield C.M., Ireland B., Kharebov A.Z., Kim J.W., et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010, 78:463-472.
41. Thrailkill K.M., Jo C.H., Cockrell G.E., Moreau C.S., Fowlkes J.L. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?. J Clin Endocrinol Metab 2011, 96:142-149.
42. Thrailkill K.M., Nimmo T., Bunn R.C., Cockrell G.E., Moreau C.S., Mackintosh S., et al. Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin. Diabetes Care 2009, 32:1266-1268.